CIS treated group showed significant decrease in SIRT1 ovarian expression by 52% compared to control group, while EMPA + CIS treated group showed significant increase in ovarian expression of SIRT1 by 102% compared to CIS treated group. The gene discussed is SIRT1; the disease is in situ carcinoma.